Maxim Kholin is the Co-Founder of Gero.ai, a global leader in aging drug discovery. Gero develops next-generation therapeutics at the intersection of physics, machine learning, and model biology, advancing proprietary drug candidates and partnering with Pfizer and Chugai (Roche group) on aging and age-related diseases.

Gero’s scientific breakthroughs include systemic rejuvenation in mammals and the first steps toward translation in dogs—a major bridge to future human studies. Its research has appeared in Science, Nature Communications, and other top journals, and has been featured in Scientific American, Popular Mechanics, and global media.

Gero pioneered Gerophysics, a new scientific discipline that applies tools from critical dynamics and statistical physics to understand and intervene in aging. In 2025, Nature recognized the field by publishing a dedicated Gerophysics Collection, establishing it as a standalone area of science.

Maxim’s mission is to radically extend healthy human life.